Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Xueqing Dou & Renchi Yang. (2019) Current and emerging treatments for immune thrombocytopenia. Expert Review of Hematology 12:9, pages 723-732.
Read now
Read now
Bryan Smith, Andrea Kiessling, Rocio Lledo-Garcia, Kate L. Dixon, Louis Christodoulou, Matthew C. Catley, Paul Atherfold, Lena E. D’Hooghe, Helene Finney, Kevin Greenslade, Hanna Hailu, Lara Kevorkian, Daniel Lightwood, Christoph Meier, Rebecca Munro, Omar Qureshi, Kaushik Sarkar, Sophie P. Shaw, Roohi Tewari, Alison Turner, Kerry Tyson, Shauna West, Stevan Shaw & Frank R. Brennan. (2018) Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. mAbs 10:7, pages 1111-1130.
Read now
Read now
Wolfgang F. Richter, Gregory J. Christianson, Nicolas Frances, Hans Peter Grimm, Gabriele Proetzel & Derry C. Roopenian. (2018) Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. mAbs 10:5, pages 803-813.
Read now
Read now
Divya Samineni, Sandhya Girish & Chunze Li. (2016) Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies. Expert Review of Clinical Pharmacology 9:12, pages 1557-1569.
Read now
Read now
Articles from other publishers (24)
Torleif Tollefsrud Gjølberg, Rahel Frick, Simone Mester, Stian Foss, Algirdas Grevys, Lene Støkken Høydahl, Øystein Kalsnes Jørstad, Tilman Schlothauer, Inger Sandlie, Morten C. Moe & Jan Terje Andersen. (2022) Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life. Communications Biology 5:1.
Crossref
Crossref
Ali Aamer Habib, Ghazaleh Ahmadi Jazi & Tahseen Mozaffar. (2020) Update on immune‐mediated therapies for myasthenia gravis. Muscle & Nerve 62:5, pages 579-592.
Crossref
Crossref
Malin Bern, Jeannette Nilsen, Mattia Ferrarese, Kine M. K. Sand, Torleif T. GjølbergHeidrun E. Lode, Robert J. DavidsonRodney M. CamireEspen S. BækkevoldStian Foss, Algirdas Grevys, Bjørn Dalhus, John WilsonLene S. Høydahl, Gregory J. Christianson, Derry C. Roopenian, Tilman SchlothauerTerje E. Michaelsen, Morten C. Moe, Silvia Lombardi, Mirko Pinotti, Inger SandlieAlessio Branchini & Jan Terje Andersen. (2020) An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Science Translational Medicine 12:565.
Crossref
Crossref
Jonathan J. Hubbard, Michal Pyzik, Timo Rath, Lisa K. Kozicky, Kine M.K. Sand, Amit K. Gandhi, Algirdas Grevys, Stian Foss, Susan C. Menzies, Jonathan N. Glickman, Edda Fiebiger, Derry C. Roopenian, Inger Sandlie, Jan Terje Andersen, Laura M. Sly, Kristi Baker & Richard S. Blumberg. (2020) FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex–driven autoimmunity. Journal of Experimental Medicine 217:10.
Crossref
Crossref
Douglas B. Cines, Sergei Zaitsev, Lubica Rauova, Ann H. Rux, Victoria Stepanova, Sriram Krishnaswamy, Amrita SarkarM. Anna KowalskaGuohua ZhaoAlan E. Mast, Laurence J. Blumberg, Keith R. McCrae, Mortimer Poncz, Jonathan J. Hubbard, Michal Pyzik & Richard S. Blumberg. (2020) FcRn augments induction of tissue factor activity by IgG-containing immune complexes. Blood 135:23, pages 2085-2093.
Crossref
Crossref
Kyungbo Kim, Pereira Araujo, Nikhil Hebbar, Ziyuan Zhou, Xirong Zheng, Fang Zheng, Vivek M Rangnekar & Chang-Guo Zhan. (2019) Development of a novel prostate apoptosis response-4 (Par-4) protein entity with an extended duration of action for therapeutic treatment of cancer. Protein Engineering, Design and Selection 32:3, pages 159-166.
Crossref
Crossref
L. J. Blumberg, J. E. HumphriesS. D. JonesL. B. PearceR. HolgateA. Hearn, J. CheungA. Mahmood, B. Del Tito, J. S. GraydonL. E. StolzA. Bitonti, S. PurohitD. de Graaf, K. Kacena, J. T. AndersenG. J. ChristiansonD. C. RoopenianJ. J. HubbardA. K. GandhiK. Lasseter, M. Pyzik & R. S. Blumberg. (2019) Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses. Science Advances 5:12.
Crossref
Crossref
Tommy Li & Joseph P. Balthasar. (2019) Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting the Effects of Anti-FcRn Therapy on the Disposition of Endogenous IgG in Humans. Journal of Pharmaceutical Sciences 108:1, pages 714-724.
Crossref
Crossref
Tommy Li & Joseph P. Balthasar. (2019) Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys. Journal of Pharmaceutical Sciences 108:1, pages 701-713.
Crossref
Crossref
Matthew G. Zimmerman, Kendra M. Quicke, Justin T. O'Neal, Nitin Arora, Deepa Machiah, Lalita Priyamvada, Robert C. Kauffman, Emery Register, Oluwaseyi Adekunle, Dominika Swieboda, Erica L. Johnson, Sarah Cordes, Lisa Haddad, Rana Chakraborty, Carolyn B. Coyne, Jens Wrammert & Mehul S. Suthar. (2018) Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages. Cell Host & Microbe 24:5, pages 731-742.e6.
Crossref
Crossref
Algirdas Grevys, Jeannette Nilsen, Kine M. K. Sand, Muluneh B. Daba, Inger Øynebråten, Malin Bern, Martin B. McAdam, Stian Foss, Tilman Schlothauer, Terje E. Michaelsen, Gregory J. Christianson, Derry C. Roopenian, Richard S. Blumberg, Inger Sandlie & Jan Terje Andersen. (2018) A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nature Communications 9:1.
Crossref
Crossref
Daniel C. Ferguson & Javier G. Blanco. (2018) Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181. Pharmaceutical Research 35:1.
Crossref
Crossref
Tomohisa Saito, Satofumi Iida, Kimio Terao & Yuji Kumagai. (2017) Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation. The Journal of Clinical Pharmacology 57:12, pages 1564-1572.
Crossref
Crossref
Peter Kiessling, Rocio Lledo-Garcia, Shikiko WatanabeGrant LangdonDiep TranMuhammad BariLouis ChristodoulouEmma JonesGraham Price, Bryan SmithFrank BrennanIan White & Stephen Jolles. (2017) The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. Science Translational Medicine 9:414.
Crossref
Crossref
Michal PyzikTimo RathTimothy T. KuoSanda WinKristi BakerJonathan J. HubbardRosa GrenhaAmit GandhiThomas D. KrämerAdam R. MezoZachary S. Taylor, Kevin McDonnellVicki NienaberJan Terje AndersenAtsushi MizoguchiLaurence BlumbergShalaka PurohitSusan D. JonesGreg Christianson, Wayne I. LencerInger SandlieNeil KaplowitzDerry C. Roopenian & Richard S. Blumberg. (2017) Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. Proceedings of the National Academy of Sciences 114:14.
Crossref
Crossref
Jaleh Barar, Mohammad A. Rafi, Mohammad M. Pourseif & Yadollah Omidi. (2016) Blood-brain barrier transport machineries and targeted therapy of brain diseases. BioImpacts 6:4, pages 225-248.
Crossref
Crossref
Yangsheng Qiu, Wei Lv, Min Xu & Yuhong Xu. (2016) Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo. Journal of Controlled Release 229, pages 37-47.
Crossref
Crossref
Stian Foss, Algirdas Grevys, Kine Marita Knudsen Sand, Malin Bern, Pat Blundell, Terje E. Michaelsen, Richard J. Pleass, Inger Sandlie & Jan Terje Andersen. (2016) Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization. Journal of Controlled Release 223, pages 42-52.
Crossref
Crossref
Algirdas Grevys, Malin Bern, Stian Foss, Diane Bryant Bratlie, Anders Moen, Kristin Støen Gunnarsen, Audun Aase, Terje Einar Michaelsen, Inger Sandlie & Jan Terje Andersen. (2015) Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. The Journal of Immunology 194:11, pages 5497-5508.
Crossref
Crossref
A. Bundhoo, S. Paveglio, E. Rafti, A. Dhongade, R. S. Blumberg & A. P. Matson. (2015)
Evidence that
F
c
R
n mediates the transplacental passage of maternal IgE in the form of
I
g
G
anti‐
I
g
E
/
I
g
E
immune complexes
. Clinical & Experimental Allergy 45:6, pages 1085-1098.
Crossref
Crossref
Angela SchochHubert Kettenberger, Olaf Mundigl, Gerhard Winter, Julia Engert, Julia HeinrichThomas Emrich. (2015) Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proceedings of the National Academy of Sciences 112:19, pages 5997-6002.
Crossref
Crossref
Arjan van der Flier, Zhan Liu, Siyuan Tan, Kai Chen, Douglas Drager, Tongyao Liu, Susannah Patarroyo-White, Haiyan Jiang & David R. Light. (2015) FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes. PLOS ONE 10:4, pages e0124930.
Crossref
Crossref
Kine Marita Knudsen Sand, Bjørn Dalhus, Gregory J. Christianson, Malin Bern, Stian Foss, Jason Cameron, Darrell Sleep, Magnar Bjørås, Derry C. Roopenian, Inger Sandlie & Jan Terje Andersen. (2014) Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-blocking Antibodies. Journal of Biological Chemistry 289:24, pages 17228-17239.
Crossref
Crossref
Dilip K. Challa, Ramraj Velmurugan, Raimund J. Ober & E. Sally Ward. 2014. Fc Receptors. Fc Receptors
249
272
.